Rigshospitalet Patent applications |
Patent application number | Title | Published |
20150057325 | COMPOUNDS CAPABLE OF MODULATING/PRESERVING ENDOTHELIAL INTEGRITY FOR USE IN PREVENTION OR TREATMENT OF ACUTE TRAUMATIC COAGULOPATHY AND RESUSCITATED CARDIAC ARREST - The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute traumatic coagulopathy (ATC) and of patients resuscitating from cardiac arrest. The invention also relates to a method of identifying individuals at risk of developing ATC. | 02-26-2015 |
20140341807 | PET TRACER FOR IMAGING OF NEUROENDOCRINE TUMORS - There is provided a radiolabelled peptide-based compound for diagnostic imaging using positron emission tomography (PET). The compound may thus be used for diagnosis of malignant diseases. The compound is particularly useful for imaging of somatostatin overexpression in tumors, wherein the compound is capable of being imaged by PET when administered with a target dose in the range of 150-350 MBq, such as 150-250 MBq, preferable in the range of 191-210 MBq. | 11-20-2014 |
20140272998 | DIAGNOSTIC MICRORNA PROFILING IN CUTANEOUS T-CELL LYMPHOMA (CTCL) - The present invention relates to the field of cancer-diagnostics. In particular the invention relates to a microRNA expression signature that allows discriminating skin samples of cutaneous T-cell lymphomas (CTCL) from non-malignant (inflammantory) skin samples by use of quantitative polymerase chain reaction performed on reverse transcribed miRNA. miR-155, miR-326, miR-663b, miR-203 and miR-205 are shown to be differentially expressed. | 09-18-2014 |
20140120105 | THERAPEUTIC TARGETING OF FICOLIN-3 - The present Invention relates to novel antibodies against Ficolin-3, which antibodies inhibit complement activation. The invention further relates to the use of anti-Ficolin-3 antibodies in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases, as well as the use as biomarkers. The present invention further relates to nucleic acid molecules encoding such antibodies, vectors and host cells used in the production of the antibodies. | 05-01-2014 |
20140044797 | PROSTACYCLIN AND ANALOGS THEREOF ADMINISTERED DURING SURGERY FOR PREVENTION AND TREATMENT OF CAPILLARY LEAKAGE - The present invention relates to the novel use of prostacyclin analogs for prevention and/or treatment of capillary leakage during surgery. The treatment of the present invention mediates discrete or minimal effects on haemostasis and vasodilation. Thus the present invention provides prostacyclin and analogs thereof for treatment which prevents capillary leakage while minimizing the risk of bleeding. The present invention further provides pharmaceutical compositions and kits of parts comprising prostacyclin or analogs thereof, and methods for treatment. | 02-13-2014 |
20130274133 | GENETIC VARIATIONS IN THE INTERLEUKIN-6 RECEPTOR GENE AS PREDICTORS OF THE RESPONSE OF PATIENTS TO TREATMENT WITH INTERLEUKIN-6 RECEPTOR INHIBITORS - The present invention relates to a method for predicting the response of patients to treatment with Interleukin-6 Receptor (IL6R) inhibitors, such as antibodies directed against the IL6R. The method comprises the analysis of one or more genetic variations, in particular single nucleotide polymorphisms, in or associated with the Interleukin-6 Receptor gene. The present invention further relates to a kit for use in predicting the response of patients to treatment with IL6R inhibitors, such as Tocilizumab. The patients suffers from rheumatoid arthritis. | 10-17-2013 |
20130261177 | COMPOUNDS CAPABLE OF MODULATING/PRESERVING ENDOTHELIAL INTEGRITY FOR USE IN PREVENTION OR TREATMENT OF ACUTE TRAUMATIC COAGULOPATHY AND RESUSCITATED CARDIAC ARREST - The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute traumatic coagulopathy (ATC) and of patients resuscitating from cardiac arrest. The invention also relates to a method of identifying individuals at risk of developing ATC. | 10-03-2013 |
20130093866 | OPTICAL MOTION TRACKING OF AN OBJECT - The present invention relates to a system and a method for monitoring/tracking the movement of an object in a location which is difficult to access, such as the movement of a patient in a clinical MRI scanner. This is achieved by an optical motion tracking system for determining the movement of an object at least partly located in a volume of difficult access and/or at least partly located in an electromagnetic field, said system comprising a borescope for imaging a pattern on the object or a surface part of the object with a camera, said pattern or surface part located adjacent to a distal end of the borescope and said camera attached to a proximal end of said borescope, and image processing means for calculating the movement of said pattern or surface part relative to the distal end of the borescope based on a plurality of frames/images captured by the camera. The invention further relates to the use of a borescope for motion tracking of an object and a marker plate suitable for use in the motion tracking system. | 04-18-2013 |
20120282285 | MASP ISOFORMS AS INHIBITORS OF COMPLEMENT ACTIVATION - The present invention relates to novel ficolin-associated polypeptides, and polypeptides derived from these ficolin-associated polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases, as well as the use as biomarkers. The present invention further relates to anti-bodies recognising such novel ficolin-associated polypeptides, and polypeptides derived thereof, nucleic acid molecules encoding such polypeptides, vectors and host cells used in the production of the polypeptides. | 11-08-2012 |
20120101004 | FICOLIN-3 ASSAY - The present invention relates to methods for detecting Ficolin-3 dependent activation of the lectin pathway of complement, methods for identifying abnormalities in Ficolin-3, and methods for screening for deficiencies/and or identifying abnormalities in any downstream components of the Ficolin-3 dependent activation of the lectin pathway of 5 complement using an acetylated Ficolin-3 ligand, said methods generally comprising the steps of: (a) providing a sample of blood, serum, plasma, another body fluid or an extract thereof; (b) (optionally) preventing in the sample activation of the classical pathway and/or the alternative pathway and/or any non-Ficolin-3 mediated activation of the lectin pathway; (c) acetylating a molecule; (d) contacting said acetylated molecule 10 with said sample, in conditions that permit specific binding of Ficolin-3 to said acetylated molecule, and, (e) detecting and quantifying specific binding of the Ficolin-3 to said acetylated molecule, (f) determining in the sample complement activation and/or deposition by the detection of a C2, C3, C4 and/or a C5 cleavage product and/or by detecting any of the terminal complement complex components C6, C7, C8 or C9 or 15 the C5b-9 terminal complement complex as such. The present invention also provides assays and kits comprising the methods of the invention. | 04-26-2012 |
20120021937 | DETECTION OF CARCINOMA IN SITU IN SEMEN SPECIMENS - The present invention provides a method for the detection of testicular cancer and/or precursors hereof by screening a sample for the presence of at least two markers in the same cell, wherein the sample is a semen sample and/or an ejaculate from a male human being. | 01-26-2012 |
20110294148 | TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER AND POSTOPERATIVE MARKER FOR MINIMAL RESIDUAL DISEASE OR RECURRENT DISEASE IN PATIENTS WITH A PRIOR HISTORY OF CANCER - The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA. | 12-01-2011 |
20110070601 | CLASSIFICATION OF INDIVIDUALS SUFFERING FROM CARDIOVASCULAR DISEASES ACCORDING TO SURVIVAL PROGNOSES AS FOUND BY MEASURING THE LEVELS OF BIOMARKER YKL-40 - The present invention relates to the method of measuring the YKL-40 level and using this measurement as a prognosis for survival of an individual suffering from heart disease caused by atherosclerosis. The method may be used for classification of individuals in order to optimize treatment or monitoring the individuals during the course of or prior to or after treatment. The individual may suffer from any type of cardiovascular disease or disorder. The method also detects and determines whether diagnostically or prognostically significant levels of YKL-40 molecules are present in a biological sample. Furthermore the level of YKL-40 may be used to predict disease relapse. | 03-24-2011 |
20110060529 | TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER - The present invention describes a method for determining whether an individual is likely to suffer from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. | 03-10-2011 |
20110045518 | YKL-40 AS A GENERAL MARKER FOR NON-SPECIFIC DISEASE - The present invention relates to methods of diagnosing the presence of a non-specific disease or disorder in a subject, wherein a determined level of YKL-40 above a reference level indicates the presence of a non-specific disease or disorder. The subject may suffer from a variety of diseases or disorders. The reference level may be a reference level obtained from healthy individuals or it may be a previous measurement obtained from the same subject. The present invention furthermore relates to a method for classifying the severity of a non-specific disease or disorder in a subject, wherein a determined level of YKL-40 above or below one or more reference levels gives the severity of said non-specific disease or disorder. The present invention further relates to a kit and a device that may be used in the method of the present invention comprising means for measuring the level of YKL-40 in a sample; and means for comparing the measured level of YKL-40 with at least one reference level of YKL-40. | 02-24-2011 |
20080261246 | TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER AND POSTOPERATIVE MARKER FOR MINIMAL RESIDUAL DISEASE OR RECURRENT DISEASE IN PATIENTS WITH A PRIOR HISTORY OF CANCER - The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA. | 10-23-2008 |